Eriacta is a prescription medication containing sildenafil citrate, a potent phosphodiesterase type 5 (PDE5) inhibitor clinically proven to treat erectile dysfunction. By enhancing blood flow to the penile tissues, it facilitates the achievement and maintenance of erections sufficient for sexual activity. This medication requires sexual stimulation for efficacy and is not an aphrodisiac. Eriacta represents a well-established therapeutic option with a robust safety profile when used under appropriate medical supervision.

Features

• Active ingredient: Sildenafil citrate 100 mg
• Mechanism: Selective inhibition of phosphodiesterase type 5 (PDE5)
• Onset of action: Typically within 30–60 minutes post-administration
• Duration of effect: Up to 4–6 hours
• Administration: Oral tablet, taken with or without food (though high-fat meals may delay absorption)
• Manufacturer compliance: Produced under strict GMP standards

Benefits

• Clinically demonstrated improvement in erectile function across various etiologies
• Enables reliable achievement and maintenance of erection with sexual stimulation
• Supports restoration of sexual confidence and intimate relationship satisfaction
• Flexible timing of administration due to extended therapeutic window
• Well-characterized pharmacokinetic and safety profile based on extensive clinical data
• Cost-effective alternative to brand-name sildenafil formulations

Common use

Eriacta is primarily indicated for the treatment of erectile dysfunction (ED) in adult males. It is used to facilitate the achievement and maintenance of an erection adequate for satisfactory sexual performance. It may be prescribed for ED resulting from various underlying conditions, including vascular, neurological, psychological, or mixed etiology. Off-label uses are determined solely by a prescribing physician based on individual clinical assessment.

Dosage and direction

The recommended starting dose for most patients is 50 mg taken approximately one hour before anticipated sexual activity. Based on efficacy and tolerability, the dose may be adjusted to a maximum of 100 mg or decreased to 25 mg. Dosage should not exceed once per 24-hour period. Tablets should be swallowed whole with a glass of water; crushing or splitting is not advised. Sexual stimulation is required for the medication to produce an effect.

Precautions

Prior to initiation, a comprehensive medical evaluation should be conducted to assess cardiovascular status, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical penile deformities, bleeding disorders, or active peptic ulceration. Avoid consumption of grapefruit or grapefruit juice, which may increase sildenafil concentrations. Patients should be advised that Eriacta offers no protection against sexually transmitted infections. Regular follow-up with a healthcare provider is recommended to monitor treatment response and tolerability.

Contraindications

Eriacta is contraindicated in patients using any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors, due to the risk of profound hypotension. Additional contraindications include hypersensitivity to sildenafil or any excipients in the formulation, severe hepatic impairment (Child-Pugh class C), severe hypotension (BP <90/50 mmHg), recent stroke or myocardial infarction, and hereditary degenerative retinal disorders such as retinitis pigmentosa.

Possible side effects

Common adverse reactions (≥1%) include headache, flushing, dyspepsia, nasal congestion, dizziness, and visual disturbances (such as altered color perception, blurred vision, or increased light sensitivity). Less frequently reported effects include nausea, rash, palpitations, and myalgia. Priapism (prolonged and painful erection lasting more than 4 hours) is a rare but serious adverse event requiring immediate medical intervention to prevent permanent tissue damage.

Drug interaction

Concomitant use with nitrates is absolutely contraindicated. Alpha-blockers may potentiate hypotensive effects—dosing separation or avoidance is advised. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) can increase sildenafil exposure, necessitating dose adjustment. Inducers of CYP3A4 (e.g., rifampin, carbamazepine) may reduce efficacy. Caution is advised with other antihypertensives due to additive blood pressure-lowering effects.

Missed dose

Eriacta is not intended for regular daily dosing; it is taken on an as-needed basis. If a dose is missed, it may be taken at any time prior to sexual activity, provided that at least 24 hours have passed since the last dose. Do not double the dose to compensate for a missed one.

Overdose

In cases of suspected overdose, standard supportive measures should be employed. Expected effects may mirror those of side effects but with greater severity, including severe hypotension, syncope, and prolonged erection. Medical attention should be sought immediately. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature (15–30°C) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing an existing treatment regimen. Do not disregard or delay seeking medical advice based on content provided here.

Reviews

Clinical studies and post-marketing surveillance indicate high patient satisfaction with Eriacta, with many reporting significant improvement in erectile function and overall sexual experience. Common feedback highlights its reliability, rapid onset, and duration of action. Some users note mild and transient side effects which often diminish with continued use. Individual responses may vary; adherence to prescribed dosage and medical guidance is essential for optimal outcomes.